A206650 Stock Overview
A biopharmaceutical company, provides vaccines for epidemics in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
EuBiologics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩13,150.00 |
| 52 Week High | ₩18,800.00 |
| 52 Week Low | ₩8,740.00 |
| Beta | 1.25 |
| 11 Month Change | 7.52% |
| 3 Month Change | 12.49% |
| 1 Year Change | 41.70% |
| 33 Year Change | -62.21% |
| 5 Year Change | 99.85% |
| Change since IPO | 159.37% |
Recent News & Updates
Investors Holding Back On EuBiologics Co., Ltd. (KOSDAQ:206650)
Aug 12
Is EuBiologics (KOSDAQ:206650) A Risky Investment?
May 30Shareholder Returns
| A206650 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -15.8% | -5.8% | -2.8% |
| 1Y | 41.7% | 28.2% | -3.4% |
Return vs Industry: A206650 exceeded the KR Biotechs industry which returned 28.2% over the past year.
Return vs Market: A206650 exceeded the KR Market which returned -3.4% over the past year.
Price Volatility
| A206650 volatility | |
|---|---|
| A206650 Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A206650's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A206650's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 310 | Yeong-Ok Baik | www.eubiologics.com |
EuBiologics Co., Ltd., a biopharmaceutical company, provides vaccines for epidemics in South Korea. It offers Euvichol Plus, an oral cholera prevention vaccine; and rCRM197, a diphtheria toxoid vaccine. The company also provides EcML, a vaccine for cell membrane, as well as offers COVID-19 diagnostic kits.
EuBiologics Co., Ltd. Fundamentals Summary
| A206650 fundamental statistics | |
|---|---|
| Market cap | ₩480.43b |
| Earnings (TTM) | -₩13.88b |
| Revenue (TTM) | ₩69.37b |
6.9x
P/S Ratio-34.6x
P/E RatioIs A206650 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A206650 income statement (TTM) | |
|---|---|
| Revenue | ₩69.37b |
| Cost of Revenue | ₩35.40b |
| Gross Profit | ₩33.96b |
| Other Expenses | ₩47.84b |
| Earnings | -₩13.88b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -379.89 |
| Gross Margin | 48.96% |
| Net Profit Margin | -20.01% |
| Debt/Equity Ratio | 11.7% |
How did A206650 perform over the long term?
See historical performance and comparison